[{"id":"4dadd4ae-dbb6-4fb0-9f33-624ca74527af","acronym":"NAVIG-1","url":"https://clinicaltrials.gov/study/NCT06622434","created_at":"2025-02-26T10:34:43.693Z","updated_at":"2025-02-26T10:34:43.693Z","phase":"Phase 1/2","brief_title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","source_id_and_acronym":"NCT06622434 - NAVIG-1","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PTPRZ1","pipe":"","alterations":" ","tags":["PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/08/2024","start_date":" 11/08/2024","primary_txt":" Primary completion: 05/08/2027","primary_completion_date":" 05/08/2027","study_txt":" Completion: 05/08/2027","study_completion_date":" 05/08/2027","last_update_posted":"2024-12-04"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"97e62d22-5c2a-48cf-89a8-1d7fd9cf36d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02978261","created_at":"2022-05-20T04:57:27.170Z","updated_at":"2024-07-02T16:36:49.173Z","phase":"Phase 1","brief_title":"Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas","source_id_and_acronym":"NCT02978261","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" PTPRZ1","pipe":"","alterations":" ","tags":["PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-03-04"}]